Bristol-Myers Squibb pays $14 million to resolve China FCPA offenses

By Richard L. Cassin, Published on The FCPA Blog on October 5th, 2015 The Securities and Exchange Commission said Monday that Bristol-Myers Squibb agreed to settle charges that its joint venture in China made cash payments and provided other benefits to health care providers at state-owned and state-controlled hospitals in exchange for prescription sales. –…